Two-Year Data for Ixekizumab in Pediatric Psoriasis Reported Two-Year Data for Ixekizumab in Pediatric Psoriasis Reported

More than half of patients had achieved 100% clearance with the IL-17 inhibitor at 2 years.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Dermatology News Source Type: news